TCTR20230711008已完成1 期
Bioequivalence study of mirabegron 50 mg in healthy Thai volunteer under fasting condition
nison Laboratories Co., Ltd.0 个研究点目标入组 46 人开始时间: 2023年7月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1. Healthy Thai male or female volunteers aged between 18 and 55 years. 2. The Body Mass Index (BMI) ranges from 18.5 to 25 kg/m2. 3. Determined healthy by medical history, physical examination and vital signs 4. The results of the clinical laboratory tests are within clinically acceptance limits i.e., blood urea nitrogen (BUN), serum creatinine, AST, ALT, total bilirubin, alkaline phosphatase, GGT, blood potassium, sodium, calcium, chloride, fasting blood sugar and hematology examinations including differential blood counts and HBsAg test. Some of the clinical laboratory values that out of the normal range will be carefully considered by clinical investigator. 5. Negative pregnancy test for female volunteers and effective contraceptive must be used at least 14 days prior to the study initiation and not breast-feeding women. 6. Male volunteers who are surgically sterile or agree to use an effective contraception throughout the study. 7. Willing to participate in the study and signed the informed consent form.
排除标准
- •1. History or evidence of allergy or hypersensitivity to mirabegron or any of the excipients of this product or any related drugs. 2. History or evidence of allergy or hypersensitivity to heparin. 3. History or evidence of hypertension (systolic BP 140 mmHg, diastolic BP 90 mmHg) or hypotension (systolic BP <90 mmHg, diastolic BP <60 mmHg). 4. History or evidence of gastrointestinal, hepatic, renal, cardiovascular, hematological disease or allergic disease or bronchial asthma or any disease that may affect the bioavailability of drug. 5. Evidence of more than one abnormal ECG which is considered as clinically significant. 6. History of chronic or debilitating diseases. 7. Positive HBsAg tests. 8. History of alcoholism or drug abuse. 9. Positive urine drug abuse tests (Benzodiazepines, Methamphetamine and Opiates). 10. History of regular alcohol consumption (more than 1 time a week) or alcohol consumption within 7 days prior to the study drug administration and until the completion of the study. 11. History of smoking more than 10 cigarettes/day, or moderate smokers (less than 10 cigarettes/day) and could not quit at least 7 days prior to the study drug administration and until the completion of the study. 12. Tea/coffee or caffeine- or xanthine-containing beverage consumption within 7 days prior to the study drug administration and until the completion of the study. 13. Grapefruit juice or grapefruit-containing products consumption within 7 days prior to the study drug administration and until the completion of the study. 14. Use of any prescription drugs or over-the-counter (OTC) drugs or herbal medicines within 30 days or vitamins or food supplements within 14 days prior to the study drug administration or use hormonal methods of contraception with-in 28 days (discontinuation for at least 6 months is required for Depo-Provera use) prior to receiving the first dose of the study medication. 15. Blood donation or blood loss over 350 mL within 90 days before the study. 16. Participation in any clinical studies within 90 days before the study.
研究者
相似试验
已完成
不适用
Bioequivalence study of mirabegron 50 mg in healthy Thai volunteer.Bioequivalence Study of Mirabegron PR tablet 50 mgTCTR20201019002nison Laboratories Co., Ltd.92
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.Urologic DiseasesUrinary Bladder, OveractiveUrinary Bladder DiseasesNCT01638000Astellas Pharma Europe Ltd.1,887
Unknown
2 期
Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord InjurySpinal Cord InjuriesUrinary Bladder, NeurogenicNCT03187795Kessler Foundation62
已完成
不适用
Examination the efficacy of Mirabegron on patient with overactive bladder after treatment with a1 blocker for benign prostatic hyperplasiaOveractive bladderJPRN-UMIN000019735Department of Urology, Shiga University of medical Science20
尚未招募
4 期
Comparing the efficacy of Mirabegron in reducing urinary symptoms associated with cerebrovascular accidentsCTRI/2023/03/050511DEPARTMENT OF UROLOGY KASTURBA MEDICAL COLLEGE MANIPA